Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like AI-Driven Patient Identification and Recruitment Solutions for Trial Design Challenges in Rare Disease Trials Innovating Clinical Outcome Assessments in Rare Disease Trials: Integrating Patient-Centered Measures and Digital Health Technologies Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development
Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like AI-Driven Patient Identification and Recruitment Solutions for Trial Design Challenges in Rare Disease Trials Innovating Clinical Outcome Assessments in Rare Disease Trials: Integrating Patient-Centered Measures and Digital Health Technologies Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development
